Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
IPO Year: 2021
Exchange: NASDAQ
Website: designtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $6.00 → $12.00 | Neutral → Overweight | Piper Sandler |
| 11/14/2023 | $42.00 → $6.00 | Overweight → Neutral | Piper Sandler |
| 8/15/2023 | $19.00 → $6.00 | Outperform → Neutral | Wedbush |
| 8/15/2023 | $23.00 → $7.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/15/2023 | $6.00 | Outperform → Market Perform | SVB Securities |
| 5/4/2023 | $6.00 | Sell → Neutral | Goldman |
| 6/10/2022 | $21.00 | Outperform | Wedbush |
| 5/2/2022 | $30.00 | Outperform | RBC Capital Mkts |
| 1/19/2022 | $10.00 | Sell | Goldman Sachs |